Results 1 to 10 of about 8,454 (202)
Frontiers in Pharmacology, 2020 Background and PurposeRabeprazole, a proton pump inhibitor (PPIs) is much endorsed to patients with increased gastric acidity. PPIs were accused to have osteoporotic effects on patients who chronically use them. The point of the current investigation was
Aly A M Shaalan +2 more
exaly +3 more sources
Vitamin B12 Deficiency Associated with Metformin and Proton Pump Inhibitors and Their Combinations: Results from a Disproportionality and Interaction Analysis [PDF]
DiseasesBackground: Metformin and proton pump inhibitors (PPIs) are independently associated with vitamin B12 deficiency. Despite frequent co-prescription, particularly in diabetics with gastroesophageal disorders, evidence regarding the combined risk of these ...
Kannan Sridharan
doaj +2 more sources
Bioequivalence of a single dose of two palbociclib formulations in healthy Chinese subjects under fasting conditions: a two-period crossover study with rabeprazole pre-treatment [PDF]
Frontiers in PharmacologyObjectivesThis study assessed the pharmacokinetics, safety, and bioequivalence of generic and original palbociclib tablets in healthy Chinese subjects under fasting conditions with rabeprazole pre-treatment.MethodsThis was a single-dose, randomized, open-
Wanjun Bai +12 more
doaj +2 more sources
Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2021 Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (
O. D. Lopina +2 more
doaj +1 more source
Pharmacokinetics and pharmacodynamics of injectable dex-rabrazole for healthy people
Di-san junyi daxue xuebao, 2021 Objective To study the pharmacokinetic and pharmacodynamic characteristics of dex-rabeprazole for injection at different doses in healthy subjects and to evaluate its safety.
YU Mingjie +5 more
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2022 To investigate the therapeutic effect of rabeprazole and rebamipide on patient age over 60 with dual antiplatelet therapy (DAPT)–related upper gastrointestinal hemorrhage following percutaneous coronary intervention (PCI).
Rong-Jie Jia MD +6 more
doaj +1 more source
Biomedicines, 2023 Rabeprazole is a proton pump inhibitor that inhibits gastric acid production and increases gastric pH; it is widely used clinically as a treatment option for gastritis and gastric ulcers.
Seung-Hyun Jeong +2 more
doaj +1 more source
Journal of Enzyme Inhibition and Medicinal Chemistry, 2023 Trypanosoma cruzi is the causative agent of American trypanosomiasis, which mainly affects populations in Latin America. Benznidazole is used to control the disease, with severe effects in patients receiving this chemotherapy.
Itzhel García-Torres +9 more
doaj +1 more source
Chinese Medical Journal, 2022 . Background:. The pharmacokinetic and clinical behaviors of many proton pump inhibitors (PPIs) in peptic ulcer treatment are altered by CYP2C19 genetic polymorphisms.
Huiyun Zhu +13 more
doaj +1 more source
Gut and Liver, 2023 Background/Aims: Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, real-world clinical data regarding this drug are scarce.
Yoon Suk Jung +6 more
doaj +1 more source